BENORILATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H15NO5
Molecular Weight	313.3047
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)NC1=CC=C(OC(=O)C2=C(OC(C)=O)C=CC=C2)C=C1

InChI

InChIKey=FEJKLNWAOXSSNR-UHFFFAOYSA-N

InChI=1S/C17H15NO5/c1-11(19)18-13-7-9-14(10-8-13)23-17(21)15-5-3-4-6-16(15)22-12(2)20/h3-10H,1-2H3,(H,18,19)

HIDE SMILES / InChI

Molecular Formula	C17H15NO5
Molecular Weight	313.3047
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://imr.sagepub.com/content/1/1/65.full.pdf
Curator's Comment: description was created based on several sources, including: www.drugfuture.com/mt/bendazac.pdf http://pmmp.cnki.net/Resources/CDDPdf/med%5Cbase%5C%E7%A5%9E%E7%BB%8F%E7%B3%BB%E7%BB%9F%E8%8D%AF%E7%89%A9%5C259.pdf http://ru.medicina-617.medicina.eh.org.ua/42.htm https://en.wikipedia.org/wiki/Benorilate

Benorilate is an aspirin-paracetamol ester with analgesic, antiinflammatory, and antipyretic properties. After absorption, it is rapidly metabolised to salicylate and paracetamol. It has been used orally in the treatment of mild to moderate pain and fever. It has also been used in osteoarthritis, rheumatoid arthritis, and soft-tissue rheumatism. Associated adverse reactions: nausea, diarrhea or constipation, digestive disorders or heartburn, occasionally - a transient skin rash, and sleepiness. Benoral should not be administered concomitantly with probenecid or any other uricosuric agents that decrease tubular reabsorption as any form of salicylate antagonises this effect when given in doses of less than 5 gm per day.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
prostaglandin biosynthetic process 23 Target ID: GO:0001516 Sources: Rheumatology (1973) XII (suppl): 101-105 doi:10.1093/rheumatology/XII.suppl.101	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Rheumatoid arthritis 316 Sources: http://imr.sagepub.com/content/1/1/65.full.pdf	Palliative	Withdrawn	Unknown Approved Use Benorylate is indicated in the treatment of rheumatoid arthritis.
Osteoarthritis 157 Sources: http://imr.sagepub.com/content/1/1/65.full.pdf	Palliative	Withdrawn	Unknown Approved Use Benorylate is indicated in the treatment of osteoarthritis.
Painful musculoskeletal conditions 3 Sources: http://imr.sagepub.com/content/1/1/65.full.pdf	Palliative	Withdrawn	Unknown Approved Use Benorylate is indicated in the treatment of painful musculoskeletal conditions.

PubMed

Title	Date	PubMed
Comparison of aspirin and benorylate in the treatment of rheumatoid arthritis.	1972 May 27	4555545
Determination of benorilate in pharmaceutical formulations and its metabolite in urine at carbon paste electrode modified by silver nanoparticles.	2005 Sep 15	18970216
Effect of pressure on molecular and ionic motions in ultraviscous acetaminophen-aspirin mixture.	2006 Nov	16886195
Overuse of non-prescription analgesics by dental clinic patients.	2008 Dec 9	19068122
Calorimetric relaxation in pharmaceutical molecular glasses and its utility in understanding their stability against crystallization.	2008 Sep 4	18683970
Insights in to the pathogenesis of axial spondyloarthropathy based on gene expression profiles.	2009	19900269
Dielectric study of equimolar acetaminophen-aspirin, acetaminophen-quinidine, and benzoic acid-progesterone molecular alloys in the glass and ultraviscous states and their relevance to solubility and stability.	2010 Mar	19780138

Patents

Sample Use Guides

In Vivo Use Guide

The dose of benorylate is 6-8 g daily.

Route of Administration: Oral

In Vitro Use Guide

Because of the very rapid hydrolysis of benorylate by liver samples, hydrolysis conditions of 300 uM benorylate plus microsomes (4ug protein equivalent to 0,8 mg liver per incubation) were selected such that benorylate was detectable for 30 min and only 50% disappeared over the first 15 min.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 14:58:22 GMT 2023` Edited by `admin` on `Fri Dec 15 14:58:22 GMT 2023`
Record UNII	W1QX9DV96G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BENORILATE

Official Name

English

WIN 11450

Code

English

Benorilate [WHO-DD]

Common Name

English

4-ACETAMIDOPHENYL SALICYLATE ACETATE

Systematic Name

English

BENORYLATE

Common Name

English

benorilate [INN]

Common Name

English

BENORILATE [MART.]

Common Name

English

BENORYLATE [MI]

Common Name

English

WIN-11450

Code

English

FENASPRATE

Common Name

English

Classification Tree Code System Code

WHO-VATC

QN02BA10